Novartis generics subsidiary Sandoz made history ahead of the weekend after getting approval in the US for Zarxio, the first biosimilar cleared by the FDA. Zarxio (filgrastim-sndz) is a biosimilar ...

Sandoz discusses PBMs, generics and the 340B drug pricing program in its new report titled, Solving American’s Drug Shortage Dilemma, For Good. Noting that despite successes and benefits, ...

Sandoz is introducing Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz, the first and only interchangeable FDA-approved denosumab biosimilars and are approved to treat all indications of Amgen’s ...

Novo Nordisk, the Danish pharma company behind Ozempic, made a very dumb decision a few years ago that will massively eat ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Sandoz Group. MEDIA RELEASE NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN . New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further ...

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...

Novartis has restructured to focus solely on innovative branded drugs, showing double-digit growth in revenue and profit in 2024. The company is strong in oncology, cardiology, immunology, and ...

Saynor said Sandoz's North America President Keren Haruvi, who also chairs the AAM, has been meeting with White House officials nearly every week to discuss pharmaceutical imports and U.S ...

Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and ...